Bladder Cancer Clinical Trial
Official title:
Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer
NCT number | NCT03125460 |
Other study ID # | 170 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 2016 |
Est. completion date | May 2019 |
Verified date | February 2020 |
Source | Cepheid |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Status | Completed |
Enrollment | 424 |
Est. completion date | May 2019 |
Est. primary completion date | February 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Subject is = 40 years of age - Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states. - Subject is considered disease positive within 12 months (365 days) of enrollment. - At the time of the enrollment visit, the subject is scheduled for a standard of care cystoscopy which will be completed within 3 days of providing a urine specimen. - Subject has agreed to provide at least 60 mL of voided urine for study purposes at the enrollment visit. - Subject has agreed to provide at least 60 mL of voided urine for study purposes at each subsequent standard of care cystoscopy visit for at least 12 months (365 days) following enrollment if the subject will enter the Longitudinal cohort. - Any subject considered anticipatory positive at the initial visit shall be enrolled into the longitudinal cohort. For each anticipatory positive enrolled into the longitudinal cohort a random disease negative subject shall be enrolled. Exclusion - Subject has been previously enrolled into the study. - Urine specimen to be used for study purposes is from the first morning void. - Subject has had an excision procedure within six weeks (42 days) of enrollment. - The subject is not scheduled for a standard of care cystoscopy visit within 12 months (365 days) following enrollment. |
Country | Name | City | State |
---|---|---|---|
Canada | The Male/Female Health and Research Centre | Barrie | Ontario |
Canada | G Kenneth Jansz Medicine Professional Corp. | Burlington | Ontario |
Canada | Urology Associates / Urologic Medical Research | Kitchener | Ontario |
Canada | Urology Clinic of Dr. Goldfarb | North Bay | Ontario |
Canada | Urologic Clinic of Stanley Flax | North York | Ontario |
Netherlands | Radboud University Medical Center | Nijmegen | |
United States | North Idaho Urology | Coeur d'Alene | Idaho |
United States | UT Southwestern | Dallas | Texas |
United States | The Urology Center of Colorado, P.C. | Denver | Colorado |
United States | Urology Associates, P.C. | Englewood | Colorado |
United States | UroPartners | Melrose Park | Illinois |
United States | Idaho Urologic Institute | Meridian | Idaho |
United States | Five Valleys Urology | Missoula | Montana |
United States | Weill Cornell Medicine | New York | New York |
United States | Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | PAVA | Palo Alto | California |
United States | Virginia Urology | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Cepheid |
United States, Canada, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison to histology for positive or suspicious cystoscopy | Comparison to histology for positive or suspicious cystoscopy | Baseline = Subject Enrollment | |
Primary | Comparison to histology for positive or suspicious cystoscopy | Comparison to histology for positive or suspicious cystoscopy | Follow up = 12 months from Subject Enrollment (Baseline) | |
Secondary | Comparison to UroVysion and urine cytology | Urovysion and urine cytology | Baseline = Subject Enrollment | |
Secondary | Comparison to UroVysion and urine cytology | Urovysion and urine cytology | Follow up = 12 months from Subject Enrollment (Baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |